PL1608400T3 - Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 - Google Patents
Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73Info
- Publication number
- PL1608400T3 PL1608400T3 PL04721913T PL04721913T PL1608400T3 PL 1608400 T3 PL1608400 T3 PL 1608400T3 PL 04721913 T PL04721913 T PL 04721913T PL 04721913 T PL04721913 T PL 04721913T PL 1608400 T3 PL1608400 T3 PL 1608400T3
- Authority
- PL
- Poland
- Prior art keywords
- cytokine
- elevation
- induced expression
- adenosine level
- adenosine
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 102000003996 Interferon-beta Human genes 0.000 abstract 1
- 108090000467 Interferon-beta Proteins 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 229960001388 interferon-beta Drugs 0.000 abstract 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20030467A FI20030467A0 (fi) | 2003-03-28 | 2003-03-28 | Menetelmä tulehdustilojen hoitamiseen |
| US51542503P | 2003-10-30 | 2003-10-30 | |
| PCT/FI2004/000158 WO2004084933A1 (en) | 2003-03-28 | 2004-03-19 | Elevation of adenosine level by cytokine-induced expression of cd73 |
| EP04721913A EP1608400B1 (en) | 2003-03-28 | 2004-03-19 | Elevation of adenosine level by cytokine-induced expression of cd73 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1608400T3 true PL1608400T3 (pl) | 2010-11-30 |
Family
ID=33099764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04721913T PL1608400T3 (pl) | 2003-03-28 | 2004-03-19 | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7534423B2 (pl) |
| EP (1) | EP1608400B1 (pl) |
| JP (1) | JP2011225607A (pl) |
| AT (1) | ATE471720T1 (pl) |
| CA (1) | CA2519465C (pl) |
| CY (1) | CY1111215T1 (pl) |
| DE (1) | DE602004027797D1 (pl) |
| PL (1) | PL1608400T3 (pl) |
| WO (1) | WO2004084933A1 (pl) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE411058T1 (de) | 2001-10-25 | 2008-10-15 | Univ Emory | Katheter für modifizierte perfusion |
| US20070160645A1 (en) * | 2001-10-25 | 2007-07-12 | Jakob Vinten-Johansen | PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs |
| PL1608400T3 (pl) | 2003-03-28 | 2010-11-30 | Faron Pharmaceuticals Oy | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 |
| CA2592142A1 (en) * | 2004-12-22 | 2006-06-29 | Emory University | Therapeutic adjuncts to enhance the organ protective effects of postconditioning |
| FI20051003A0 (fi) * | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| US8975081B2 (en) | 2007-10-24 | 2015-03-10 | Faron Pharmaceuticals Oy | Biomarker for monitoring development of diseases and assessing the efficacy of therapies |
| FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Faron Pharmaceuticals Oy | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| US20090130092A1 (en) * | 2007-10-30 | 2009-05-21 | Pinsky David J | Nucleotide phosphate dissipation as a treatment for vascular disorders |
| US8784805B2 (en) | 2008-02-29 | 2014-07-22 | Alloksys Life Sciences B.V. | Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases |
| US20110064671A1 (en) * | 2008-03-10 | 2011-03-17 | Cornell University | Modulation of blood brain barrier permeability |
| US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| CN107441480A (zh) | 2010-06-30 | 2017-12-08 | 卡姆普根有限公司 | 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途 |
| CU23963B1 (es) * | 2011-07-01 | 2013-12-11 | Ct De Ingeniería Genética Y Biotecnología | Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas |
| US20140234373A1 (en) | 2011-09-16 | 2014-08-21 | Georfia Regents University | Methods of Promoting Immune Tolerance |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| AU2016316119A1 (en) | 2015-09-04 | 2018-04-19 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
| FI126979B (en) | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
| WO2017155981A1 (en) | 2016-03-07 | 2017-09-14 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
| US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
| CA3032826A1 (en) | 2016-08-03 | 2018-02-08 | Nextcure, Inc. | Compositions and methods for modulating lair signal transduction |
| EP4360714A3 (en) | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| RU2759334C2 (ru) | 2016-09-21 | 2021-11-12 | Нексткьюр, Инк. | Антитела против siglec-15 и способы их применения |
| CA3074641A1 (en) | 2017-09-07 | 2019-03-14 | Augusta University Research Institute, Inc. | Specific akt3 activator and uses thereof |
| US20200077906A1 (en) | 2018-09-07 | 2020-03-12 | Augusta University Research Institute, Inc. | Method and System for Monitoring Brain Function and Intracranial Pressure |
| WO2020150320A1 (en) | 2019-01-17 | 2020-07-23 | Georgia Tech Research Corporation | Drug delivery systems containing oxidized cholesterols |
| KR20230025534A (ko) | 2020-05-08 | 2023-02-21 | 조지아뮨 엘엘씨 | Akt3 조절제 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0645452A1 (en) * | 1985-10-14 | 1995-03-29 | Yeda Research And Development Co. Ltd. | Human interferon-beta 2A and interfeon-beta 2B, vectors containing genes coding for said interferons, cell lines producing same and use of said interferons as pharmaceuticals |
| GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
| WO2001023006A1 (en) * | 1999-09-28 | 2001-04-05 | Amarillo Biosciences, Inc. | Low dose ifn-gamma for treatment of disease |
| EP1372702B1 (en) | 2001-04-03 | 2007-07-18 | U-Cytech B.V. | Treatment of hypoxia/ischaemia related blood flow resistance using beta-interferon |
| WO2002089828A2 (en) | 2001-05-04 | 2002-11-14 | Institute Of Molecular And Cell Biology | Interferons in the treatment of ischemia |
| US6911198B2 (en) | 2001-09-17 | 2005-06-28 | Yeda Research And Development Co. Ltd. | Method and pharmaceutical composition for treating inflammation |
| JP2005519946A (ja) | 2002-03-12 | 2005-07-07 | マキシジェン エーピーエス | 発作の処置のためのインターフェロンβ様分子 |
| PL1608400T3 (pl) | 2003-03-28 | 2010-11-30 | Faron Pharmaceuticals Oy | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 |
-
2004
- 2004-03-19 PL PL04721913T patent/PL1608400T3/pl unknown
- 2004-03-19 WO PCT/FI2004/000158 patent/WO2004084933A1/en not_active Ceased
- 2004-03-19 EP EP04721913A patent/EP1608400B1/en not_active Expired - Lifetime
- 2004-03-19 DE DE602004027797T patent/DE602004027797D1/de not_active Expired - Lifetime
- 2004-03-19 AT AT04721913T patent/ATE471720T1/de active
- 2004-03-19 CA CA2519465A patent/CA2519465C/en not_active Expired - Lifetime
- 2004-03-19 US US10/546,653 patent/US7534423B2/en not_active Expired - Lifetime
-
2005
- 2005-10-05 US US11/242,937 patent/US7727521B2/en active Active
-
2009
- 2009-04-24 US US12/429,436 patent/US20090269303A1/en not_active Abandoned
-
2010
- 2010-08-17 CY CY20101100758T patent/CY1111215T1/el unknown
-
2011
- 2011-07-22 JP JP2011161110A patent/JP2011225607A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7534423B2 (en) | 2009-05-19 |
| EP1608400A1 (en) | 2005-12-28 |
| DE602004027797D1 (de) | 2010-08-05 |
| US20060198821A1 (en) | 2006-09-07 |
| US7727521B2 (en) | 2010-06-01 |
| US20060034801A1 (en) | 2006-02-16 |
| JP2011225607A (ja) | 2011-11-10 |
| WO2004084933A1 (en) | 2004-10-07 |
| US20090269303A1 (en) | 2009-10-29 |
| CA2519465A1 (en) | 2004-10-07 |
| CA2519465C (en) | 2016-08-02 |
| ATE471720T1 (de) | 2010-07-15 |
| EP1608400B1 (en) | 2010-06-23 |
| CY1111215T1 (el) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1608400T3 (pl) | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 | |
| TW200716612A (en) | Pyrimidine compounds | |
| UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
| AU2007257423A8 (en) | Purine analogs | |
| IN2006KO01346A (pl) | ||
| TNSN06228A1 (en) | Compounds and methods of use | |
| MY161415A (en) | A homeopathic formulation | |
| MY150602A (en) | Subtituted-quinoxaline-type piperidine compounds and the uses thereof | |
| WO2006031922A3 (en) | Thyroid hormone analogs for promoting angiogenesis | |
| MY145074A (en) | Thiazolidin-4-one derivatives | |
| WO2004058700A3 (en) | Mitotic kinesin inhibitors | |
| MX2009003911A (es) | Formulaciones de liberacion inmediata, mejoradas de topiramato. | |
| WO2004058148A3 (en) | Mitotic kinesin inhibitors | |
| CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
| MXPA05000765A (es) | Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos. | |
| MXPA05010515A (es) | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. | |
| WO2008063676A3 (en) | Treatment of injury to the brain by inhibition of acid sensing ion channels | |
| UA84404C2 (ru) | Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина | |
| BRPI0418293A (pt) | composição compreendendo um extrato aquoso de folhas de videira de uvas vermelhas e um diurético para o tratamento de insuficiências venosas crÈnicas | |
| WO2005102296A3 (en) | Combinations for the treatment of immunoproliferative skin disorders such as psoriasis | |
| WO2006068796A3 (en) | Inhibitors of akt activity | |
| TW200742580A (en) | Methods for treating nephrolithiasis | |
| WO2005092878A3 (en) | Schweinfurthin analogues | |
| BRPI0509667A (pt) | azaquinazolinas substituìdas com eficácia antiviral | |
| PL1612210T3 (pl) | Nowe analogi nitrobenzylotioinozyny |